POST-TEST

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Androgen deprivation therapy (ADT) intensification with which of the following androgen receptor pathway inhibitors prolonged PSA progression-free survival (PFS) among patients with high-risk biochemically relapsed prostate cancer in the Phase III PRESTO trial?**
   a. Abiraterone
   b. Apalutamide
   c. Enzalutamide
   d. Darolutamide

2. **Ipatasertib inhibits which of the following targets?**
   a. TROP2
   b. ESR1
   c. PI3K
   d. AKT

3. **The Phase III CAPItello-281 trial is evaluating the combination of capivasertib with ADT and abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and which of the following features?**
   a. HER2 overexpression
   b. Homologous recombination repair gene mutation
   c. TP53 mutation
   d. PTEN deficiency

4. **In the Phase III PROpel study of olaparib and abiraterone versus abiraterone alone for metastatic castration-resistant prostate cancer, which of the following statements is true regarding patients with a germline or somatic BRCA mutation?**
   a. A significant improvement in radiographic PFS (rPFS) but not overall survival (OS) in the germline BRCA-mutated population only
   b. A significant improvement in rPFS and OS in the germline BRCA-mutated population only
   c. A significant improvement in rPFS but not OS in both the germline and somatic BRCA-mutated populations
   d. A significant improvement in rPFS and OS in both the germline and somatic BRCA-mutated populations
   e. None of the above

5. **In the Phase III ARANOTE study evaluating darolutamide in combination with ADT versus ADT alone for mHSPC, what efficacy finding was reported regarding rPFS?**
   a. Inferior rPFS outcomes with the darolutamide combination
   b. No significant difference in rPFS with the darolutamide combination
   c. A significant improvement in rPFS with the darolutamide combination